Life Sciences

  • March 18, 2026

    DLA Piper Lands Shook Hardy Products Liability Pro In Miami

    A longtime Shook Hardy & Bacon LLP trial lawyer specializing in high-stakes product liability and complex litigation has joined DLA Piper in Miami, the firm announced Wednesday.

  • March 18, 2026

    Axion Cleared Of False Advertising Before Agilent Patent Trial

    Ahead of a patent infringement trial set to begin next week, a Delaware federal judge has addressed false advertising claims against biotechnology firm Axion and ruled there was no genuine dispute that a set of Axion advertisements deceived customers.

  • March 18, 2026

    Biotech Investor Blames Pierce Atwood For Messy Asset Sale

    A Ukrainian billionaire who was recently ordered to pay other investors in a failed genetic testing company more than $1.8 million in damages is blaming the Pierce Atwood LLP lawyers who advised him on what a court later found to be a "fundamentally unfair" forced asset sale.

  • March 18, 2026

    Latham Hires Desmarais IP Partner In DC

    Latham & Wakins LLP has hired a Desmarais LLP partner in D.C., who helped represent GlaxoSmithKline Biologicals in an ongoing infringement suit against Moderna Inc., the firm announced Tuesday.

  • March 17, 2026

    Pot Co. Escapes Potency Suit, Judge Warns Plaintiff Firm

    MariMed and other cannabis companies beat claims they intentionally mislabeled their products to sidestep Illinois THC potency limits, with a federal judge highlighting the string of consumer-led suit losses and warning counsel to "heed the strong and universal concerns about the plausibility of their legal theories."

  • March 17, 2026

    NeoGenomics Beats Investor Suit Over Growth Driver Claims

    Cancer diagnostics company NeoGenomics Inc. no longer faces a proposed investor class action alleging it mischaracterized its growth drivers, including by failing to disclose that a rainmaking unit potentially ran afoul of anti-kickback laws, after a Manhattan federal judge held the suit failed to show the company had intentionally misled the markets. 

  • March 17, 2026

    9th Circ. Backs Rare FCA Theory In Huge Drug Prices Program

    In a novel and potentially far-reaching decision, the Ninth Circuit on Tuesday revived a major hospital chain's False Claims Act suit accusing large pharmaceutical companies of massive overcharges in a prominent drug discount program where pricing disputes are common.

  • March 17, 2026

    Bard And AngioDynamics Resolve 11-Year Patent Dispute

    A Delaware federal judge on Tuesday closed the book on a vascular port patent dispute between C.R. Bard and AngioDynamics that had been pending for over 11 years, citing a settlement after the Federal Circuit invalidated Bard patents that a jury said AngioDynamics infringed.

  • March 17, 2026

    Dr. Oz Claims Florida Also Has Healthcare Fraud Problem

    Dr. Mehmet Oz, the administrator for the Centers for Medicare & Medicaid Services, announced Tuesday that he is taking his efforts to combat healthcare-related fraud to Florida, where he says millions of dollars have been wasted on schemes involving durable medical equipment.

  • March 17, 2026

    Geico Keeps RICO, Fraud Claims In NY No-Fault Billing Suit

    Two New York companies must face the majority of claims in Geico's suit alleging they exploited the state's no-fault insurance laws by fraudulently billing Geico more than $2.7 million for unnecessary durable medical equipment, a federal judge ruled Tuesday.

  • March 17, 2026

    Bipartisan Bill To Waive $100K H-1B Fee Gets AMA Backing

    Medical organizations and a bipartisan group of lawmakers are backing federal legislation introduced Tuesday that would exempt physicians and other healthcare workers from the Trump administration's $100,000 fee on H-1B visas.

  • March 17, 2026

    Edwards Beats Heart Valve IP Suit Just Before Trial

    A Delaware federal judge has ruled in favor of Edwards Lifesciences Corp. in a patent infringement suit brought against it by rival Aortic Innovations LLC, finding that the term "frame" as it appears in the patent claims lacks written description.

  • March 17, 2026

    Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033

    Specialty drugmaker Fennec Pharmaceuticals has jointly announced with Indian multinational pharmaceutical company Cipla Ltd. that they had reached an agreement to settle patent infringement litigation in exchange for Cipla delaying the manufacture of a generic pediatric cancer drug until 2033.

  • March 17, 2026

    Alcon Drops $430M Lensar Deal Under Pressure From FTC

    Swiss eye care company Alcon Inc. has abandoned its planned purchase of a Florida-based maker of laser treatments for cataracts, Lensar Inc., after the Federal Trade Commission threatened to block the $430 million deal.

  • March 17, 2026

    WTO Must Extend Digital Trade Protections, Lawmakers Told

    The World Trade Organization's moratorium on digital trade measures must be extended and its scope strengthened in support of U.S. business interests, experts testifying before the U.S. House's trade panel told lawmakers Tuesday.

  • March 17, 2026

    Drug Developer GNQ To Go Public Via $500M SPAC Deal

    Techbio company GNQ Insilico has announced plans to go public by merging with special-purpose acquisition company IB Acquisition Corp. in a deal that values it at $500 million and was built by four law firms.

  • March 17, 2026

    McGuireWoods Adds Former CDC Scientist From McDermott

    McGuireWoods LLP said Tuesday that it has hired a former Centers for Disease Control and Prevention scientist from McDermott Will & Schulte LLP, touting his background as a microbiologist and his history advising healthcare clients.

  • March 17, 2026

    Fenwick Healthcare Regulatory Atty Rejoins Latham In LA

    Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.

  • March 16, 2026

    1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze

    The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.

  • March 16, 2026

    Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal

    A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.

  • March 16, 2026

    Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit

    Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.

  • March 16, 2026

    J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M

    A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.

  • March 16, 2026

    Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss

    Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.

  • March 16, 2026

    Amgen And Sanofi End Repatha IP Fight Heard By Justices

    Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.

  • March 16, 2026

    Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B

    Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.

Expert Analysis

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

  • Series

    Law School's Missed Lessons: Educating Your Community

    Author Photo

    Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Adapting To USPTO's Reduction Of Examiner Interview Time

    Author Photo

    Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • 5 Crisis Lawyering Skills For An Age Of Uncertainty

    Author Photo

    As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.

  • Anticipating FTC's Shift On Unfair Competition Enforcement

    Author Photo

    As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.